Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with Immunotherapy and Anti-angiogenic Therapy in Advanced HER2-negative Breast Cancer
NCT06890871Phase 2Enrolling by invitation
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Objective Response Rate. Started Aug 2024; status: enrolling by invitation.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06890871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890871.